Morphosys’ chief scientific officer will quit after 17 years with the group, the latest change at the top of the German biotech firm as it gears up for its first product launch. The group said late on Wednesday that CSO Markus Enzelberger would step down at the end of February to explore new opportunities. The shares dropped 2.1% at 0853 GMT on Thursday as one trader pointed to Enzelberger’s “crucial position” at Morphosys. …read more
Source:: Yahoo Finance
